TPS4 Antibody

What is Thrombospondin-4 (TSP4) and why is it an important target for antibody research?

Thrombospondin-4 is a 961-amino acid adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions. It plays crucial roles in cellular proliferation, migration, adhesion, inflammatory response to CNS injury, regulation of vascular inflammation, and adaptive responses of the heart to pressure overload and in myocardial function and remodeling .

TSP-4 is localized to the endoplasmic reticulum, extracellular matrix, and is secreted from cells. It undergoes glycosylation post-translational modifications and is expressed in various tissues including testis, nasopharynx, lung, fallopian tube, and breast . Its involvement in cardiovascular pathologies makes it a significant research target, as TSP-4 has been shown to regulate vascular inflammation and atherogenesis .

How should I optimize TPS4 antibody concentration for Western blotting?

When performing Western blot with TPS4 antibodies, methodology optimization is critical for specific signal detection:

• Initial concentration determination:

  • Begin with manufacturer-recommended dilutions (typically 0.2-2 μg/mL for anti-TSP4 antibodies)

  • For human heart tissue lysates, 1 μg/mL has been validated for specific detection

• Sample preparation considerations:

  • Use reducing conditions for consistent results

  • Use appropriate buffer systems (e.g., Immunoblot Buffer Group 1 has been validated)

• Titration approach:

  • Test a dilution series (e.g., 0.1, 0.5, 1.0, 2.0 μg/mL)

  • Evaluate signal-to-noise ratio at each concentration

  • Select concentration that provides strong specific signal (130-158 kDa band) with minimal background

• Validation controls:

  • Include positive control (human heart tissue for human TSP4)

  • Include negative control (TSP4-deficient tissue or cells if available)

  • Consider using blocking peptides to confirm specificity

The expected molecular weight of TSP4 varies under different conditions: approximately 130 kDa under reducing conditions in standard Western blot and approximately 158 kDa in Simple Western™ systems .

What are the best tissue sources for TPS4 immunodetection studies?

The selection of appropriate tissue sources is critical for successful TSP4 detection:

For studying TSP4 in the context of cardiovascular disease:

• Atherosclerotic lesions show high TSP4 expression

• Areas prone to lesion development demonstrate significant TSP4 abundance

• Vascular wall tissues, particularly from ApoE−/− mice, are valuable for studying TSP4's role in inflammation

For macrophage studies, TSP4 expression can be significantly induced by LPS treatment (0.5 μg/mL) for 1-24 hours in both RAW264.7 cells and bone marrow-derived macrophages .

How do antibodies against different domains of TSP4 affect functional studies of cell adhesion and migration?

TSP4 domain-specific antibodies can yield different insights in functional studies:

• Domain-specific targeting considerations:

  • Antibodies against collagen-binding domains may primarily inhibit ECM interactions

  • Antibodies targeting integrin-binding regions specifically block cell adhesion via β2 and β3 integrins

  • C-terminal domain antibodies might affect calcium-binding functions

• Functional differences in mechanistic studies:

  • For macrophage adhesion studies: TSP4 promotes macrophage adhesion in a dose-dependent manner (up to 7-fold increase), mediated through β2 and β3 integrins

  • For migration assays: TSP4 increases macrophage migration up to 4.7-fold, with effects dependent on specific integrin interactions

  • For signaling studies: TSP4-induced adhesion leads to p38-MAPkinase activation

• Experimental approach:

  • Compare multiple domain-specific antibodies in parallel assays

  • Use specific blocking antibodies against integrins (anti-β3, anti-α5β1, anti-α4, anti-αM) to determine the contribution of each receptor type to TSP4-mediated effects

  • Correlate antibody epitope mapping with functional inhibition profiles to identify crucial TSP4 domains

When designing inhibition experiments, pre-treatment of cells with blocking antibodies (20 min at 37°C) prior to TSP4 exposure provides optimal inhibition of TSP4-mediated adhesion and migration .

What are the key considerations for studying TSP4 in atherosclerosis models using antibody-based approaches?

Studying TSP4 in atherosclerosis requires careful experimental design:

• Model selection:

  • ApoE−/− mice provide a standardized atherosclerosis model

  • Thbs4−/−/ApoE−/− double knockout mice enable studying TSP4 deficiency effects

  • Consider both diet conditions: chow diet (smaller lesions) and Western diet (larger lesions)

• Sex-specific considerations:

  • TSP4 deficiency has differential effects based on sex:

    • 48% lesion reduction in females vs. 39% in males (chow diet)

    • 30% reduction in females vs. 33% in males (Western diet)

  • Design studies with sex-matched groups and analyze data separately by sex

• Detection methodology:

  • Immunohistochemistry of lesions requires careful optimization

  • Multiple markers should be employed simultaneously:

    • Anti-TSP4 antibodies for TSP4 localization

    • Anti-CD68 for macrophage identification

    • Nuclear staining (e.g., DAPI) for cell distribution analysis

• Quantitative analysis approaches:

  • Area measurements for lesion size (Oil Red O staining)

  • Cell counting for inflammatory infiltrates

  • Quantification of nuclei area (hematoxylin staining) to assess cellularity

  • Colocalization analysis for TSP4 with inflammatory cell markers

Antibody-based detection reveals that TSP4 deficiency reduces macrophage numbers in lesions by ≥2-fold across different experimental groups, highlighting its role in inflammatory cell recruitment .

How can I validate the specificity of my TPS4 antibody?

Thorough validation of TSP4 antibodies is essential for reliable research outcomes:

• Genetic validation approaches:

  • Test antibody reactivity in Thbs4−/− (knockout) tissues as negative controls

  • Compare antibody staining patterns between wild-type and Thbs4−/− tissues

  • Verify absence of immunostaining in various tissues from Thbs4−/− mice

• Biochemical validation methods:

  • Western blot analysis to confirm detection of correct molecular weight band (130-158 kDa)

  • Immunoprecipitation followed by mass spectrometry to verify target identity

  • Preabsorption tests with recombinant TSP4 protein to demonstrate binding specificity

• Cross-reactivity assessment:

  • Test reactivity against related thrombospondin family members (TSP-1, TSP-2, TSP-3, TSP-5)

  • Some anti-TSP antibodies may show cross-reactivity with TSP-2

  • Verify lack of cross-reaction with other matrix proteins (fibronectin, fibrinogen, von Willebrand factor)

• Experimental validation:

  • Confirm expected expression patterns in tissues known to express TSP4

  • Verify inducible expression in appropriate models (e.g., LPS-induced expression in macrophages)

  • Compare results using multiple antibodies targeting different epitopes of TSP4

A comprehensive validation approach should combine multiple methods to ensure antibody specificity before proceeding with experimental applications.

What are common issues with TSP4 antibody detection in immunohistochemistry, and how can they be resolved?

Several technical challenges may arise when using TSP4 antibodies for immunohistochemistry:

• High background issues:

  • Cause: Insufficient blocking, high antibody concentration, cross-reactivity

  • Solutions:

    • Increase blocking time/concentration (e.g., 5-10% normal serum from secondary antibody species)

    • Optimize primary antibody dilution (15 μg/mL has been effective for mouse TSP4 detection)

    • Include additional blocking steps with avidin/biotin if using biotin-based detection systems

• Weak or absent signal:

  • Cause: Inadequate antigen retrieval, epitope masking, low target expression

  • Solutions:

    • Optimize antigen retrieval methods (heat-induced vs. enzymatic)

    • Use fresh tissue sections or properly stored samples

    • Extend primary antibody incubation (overnight at 4°C has been effective)

    • Use amplification systems for low abundance targets

• Non-specific staining:

  • Cause: Cross-reactivity, inadequate washing, endogenous peroxidase activity

  • Solutions:

    • Include additional washing steps with 0.1% Tween-20

    • Properly quench endogenous peroxidase (3% H₂O₂ treatment)

    • Use more specific detection systems (e.g., Anti-Rat HRP-DAB for rat monoclonal anti-mouse TSP4)

• Fixation-dependent issues:

  • Cause: Overfixation can mask epitopes, inadequate fixation can reduce tissue integrity

  • Solutions:

    • For TSP4 detection in mouse connective tissue, perfusion-fixed frozen sections have been successful

    • Compare multiple fixation methods to determine optimal protocol

    • Test freshly prepared versus stored fixed samples

Counterstaining with hematoxylin helps visualize tissue architecture while maintaining TSP4-specific staining (brown DAB signal) .

How can CRISPR-engineered cell lines facilitate TSP4 antibody validation and functional studies?

CRISPR/Cas9 technology provides powerful approaches for TSP4 antibody research:

• CRISPR knockout validation systems:

  • Generate TSP4 knockout cell lines in relevant models (e.g., endothelial cells, vascular smooth muscle cells)

  • Compare antibody reactivity between wild-type and knockout cells to confirm specificity

  • Use as negative controls for antibody optimization

• Domain-specific engineering:

  • Create cells expressing truncated or domain-mutated TSP4 variants

  • Map precise epitope recognition patterns of different antibodies

  • Similar to the approach used for TPS4/TPS10 specificity studies, where strategic mutations altered product specificity

• Tagged TSP4 expression systems:

  • Engineer cells expressing epitope-tagged TSP4 (e.g., His-tag, FLAG-tag)

  • Enable dual detection with anti-tag and anti-TSP4 antibodies

  • Facilitate pulldown experiments to identify interaction partners

• Inducible expression systems:

  • Create cell lines with doxycycline-inducible TSP4 expression

  • Generate calibration curves for antibody sensitivity assessment

  • Study temporal dynamics of TSP4 secretion and extracellular matrix incorporation

This approach builds on established methodologies where introducing specific mutations (like the combined mutations created in TPS4-c17) resulted in altered functional profiles , allowing precise correlation between sequence, structure, and antibody recognition.

How can I implement multiplexed immunofluorescence techniques to study TSP4 in the context of inflammatory processes?

Multiplexed immunofluorescence enables complex spatial analysis of TSP4 in inflammatory contexts:

• Panel design considerations:

  • Core markers: Anti-TSP4 antibody (species-specific), cell-type markers (CD68 for macrophages), nuclear stain (DAPI)

  • Additional markers: Activation markers, other ECM proteins, signaling molecules

  • Example validated panel: anti-CD68 (green), anti-TSP4 (red), DAPI (blue) for macrophage-TSP4 interactions

• Technical implementation:

  • Sequential staining approach:

    • Apply primary antibodies sequentially from different species

    • Use species-specific secondary antibodies with distinct fluorophores

    • Include blocking steps between rounds

  • Tyramide signal amplification for low-abundance targets

  • Spectral unmixing for channels with potential overlap

• Optimization steps:

  • Titrate each antibody individually before combining

  • Validate specificity using appropriate controls

  • Test order of antibody application to minimize interference

  • Optimize fixation and permeabilization for each target

• Analysis approaches:

  • Quantify colocalization between TSP4 and inflammatory cells

  • Measure TSP4 expression gradients relative to inflammatory foci

  • Perform spatial relationship analysis between TSP4 and various cell types

This approach has been successfully implemented to demonstrate TSP-4 expression in macrophages from peritoneal cavity lavage and peritoneal tissue in models of LPS-induced peritonitis, revealing increased TSP-4 in inflammatory conditions .

Comparative and Specialized Applications

TSP4 antibody applications extend to diverse pathological conditions:

• Cardiac pathologies:

  • Pressure overload and heart failure: TSP4 expression increases dramatically in response to pressure overload and in failing hearts

  • Myocardial ischemia: Anti-TSP4 can track expression changes following ischemic events

  • Methodology: Compare TSP4 levels in normal vs. pathological cardiac tissue using quantitative immunohistochemistry and Western blotting

• Thrombosis research applications:

  • Study potential associations between TSP4 and platelet activation

  • Compare with established platelet-related proteins like Platelet Factor 4 (PF4)

  • Methodology: Use similar approaches to those established for PF4 antibody detection including ELISA, latex immunoassay, and functional assays

• Inflammatory conditions:

  • LPS-induced peritonitis model: TSP4 promotes macrophage accumulation

  • Experimental approach: Compare wild-type vs. P387-TSP-4-KI mice using anti-TSP4 and anti-CD68 co-staining

  • Quantification: Count macrophages in peritoneal cavity and measure TSP4 expression by qRT-PCR (shown to increase significantly over control mice)

• Time-course studies:

  • LPS treatment of macrophages induces TSP4 expression over 1-24 hours

  • Detection methods: Western blotting with anti-TSP4 antibodies and immunofluorescence staining

  • Combined approach: Protein synthesis inhibition with cycloheximide (CHX, 25 μM) followed by LPS treatment to distinguish between new synthesis and redistribution

These approaches can be adapted from established methodologies for studying inflammatory processes similar to those documented for TSP4's role in atherosclerosis .